Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 2/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905380 | 0.89 | DRD2 (0.48) | PKMSMN1; SMN2PARP1LMNAALDH1A1 | |
| SCHEMBL1970405 | 0.81 | PKM (0.59) | PKMSMN1; SMN2MMP12PARP1NR3C2 | |
| SCHEMBL29893671 | 0.81 | PKM (0.59) | PKMSMN1; SMN2MMP12PARP1NR3C2 | |
| SCHEMBL707964 | 0.81 | PKM (0.59) | PKMSMN1; SMN2MMP12PARP1NR3C2 | |
| SCHEMBL1744758 | 0.81 | PKM (0.59) | PKMSMN1; SMN2MMP12PARP1NR3C2 | |
| SCHEMBL30197829 | 0.81 | SMN1; SMN2 (0.62) | PKMSMN1; SMN2MMP12PARP1NR3C2 | |
| SCHEMBL707711 | 0.81 | SMN1; SMN2 (0.62) | PKMSMN1; SMN2MMP12PARP1NR3C2 | |
| SCHEMBL706059 | 0.78 | PARP1 (0.62) | PKMSMN1; SMN2MMP12PARP1LMNA | |
| SCHEMBL532240 | 0.78 | GAA (0.65) | PKMNR3C2LMNAMEN1KMT2A | |
| SCHEMBL10154038 | 0.77 | SMN1; SMN2 (0.69) | PKMSMN1; SMN2MMP12PARP1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748125-B1 | METHOD FOR CONTINUOUS NUCLEOPHILIC ADDITION TO ACTIVATED MULTIPLE CARBON-CARBON BONDS | BYK CHEMIE GMBH (DE) | 2014-12-03 | — | — | EP | claimed |
| US-20140303300-A1 | METHOD FOR CONTINUOUS NUCLEOPHILIC ADDITION TO ACTIVATED CARBON-CARBON MULTIPLE BONDS | BYK-CHEMIE GMBH (DE) | 2014-10-09 | — | — | US | claimed |
| US-6951855-B2 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | claimed |
| US-20040122006-A1 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | US | claimed |
| EP-1385835-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | Astrazeneca AB (SE) | 2004-02-04 | — | — | EP | claimed |
| WO-2002085868-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| CN-111315718-B | Molecules having one hydrophobic group and two identical hydrophilic ionic groups and compositions thereof | 埃科莱布美国股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-113840945-B | Use of multi-charged cationic compounds derived from polyamines and compositions thereof for corrosion inhibition in aqueous systems | 埃科莱布美国股份有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-114478843-B | Method for terminating anionic polymerization | 财团法人工业技术研究院 | 2023-08-04 | — | — | CN | disclosed |
| CN-116396183-A | Ionic compounds derived from polyamines, compositions thereof and methods of making the same | 埃科莱布美国股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116082183-A | Multi-charged ionic compounds derived from polyamines, compositions thereof and use thereof as reverse demulsifiers for oil and gas operations | 埃科莱布美国股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-112584909-B | Multi-charged ionic compounds derived from polyamines, compositions thereof and methods of making the same | 埃科莱布美国股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-114478843-A | Method for terminating anionic polymerization | 财团法人工业技术研究院 | 2022-05-13 | — | — | CN | disclosed |
| US-5229472-A | Addition polymerization, high temperature, short residence times | SHELL OIL COMPANY (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0522641-A2 | Anionic extruder polymerization | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1993-01-13 | — | — | EP | disclosed |
| US-4764572-A | Anionic polymerization process | SHELL OIL COMPANY (US) | 1988-08-16 | — | — | US | disclosed |
| EP-0210677-A2 | Process for the anionic polymerization of monomers | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-02-04 | — | — | EP | disclosed |
| US-4379007-A | Catalysts for nitramine propellants | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1983-04-05 | — | — | US | disclosed |
| US-4279833-A | COATINGS | ASHLAND CHEMICAL COMPANY (US) | 1981-07-21 | — | — | US | disclosed |
| US-4279833-A | COATINGS | ASHLAND CHEMICAL COMPANY (US) | 1981-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122006-A1 | Benzoxazinone derivatives for use in the treatment of angiogenesis | HAX1, VEGFA, HYOU1 | PKM 4125/4885SMN1; SMN2 2387/4885MMP12 1126/4885 |
| US-20140303300-A1 | METHOD FOR CONTINUOUS NUCLEOPHILIC ADDITION TO ACTIVATED CARBON-CARBON MULTIPLE BONDS | C5, NOX5, NQO1 | PKM 1233/4885SMN1; SMN2 2656/4885MMP12 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.